New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
05:23 EDTSHPGShire executes agreements to divest Dermagraft
Shire announced that it has entered into a definitive agreement pursuant to which it has sold its Dermagraft assets to Organogenesis. Dermagraft is a living skin substitute indicated for use in the treatment of full-thickness diabetic foot ulcers and is approved for use in the US and Canada. Going forward Organogenesis will assume all financial and management responsibility for Dermagraft. The Dermagraft assets that have been sold to Organogenesis comprise the key operating assets relating to the development, manufacture and sale of the Dermagraft product. These assets include intellectual property relating to Dermagraft including patents, trademarks and know-how; regulatory filings and registrations relating to Dermagraft; certain manufacturing plant, equipment and materials; Dermagraft product inventory and accounts receivable. These assets had a value of $683M in Shire's September 30, 2013 balance sheet. Shire is generally retaining legacy liabilities relating to the Dermagraft business, including the previously announced Department of Justice investigation relating to the sales and marketing practices of Advanced Biohealing. Shire will receive no upfront payment from Organogenesis but is entitled to receive up to $300M cash in total milestone payments should Organogenesis meet certain annual net sales targets between now and 2018. Shire will record a loss on disposal and associated impairment charges of approximately $650M in Q4, which will be excluded from Non GAAP earnings.
News For SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
10:02 EDTSHPGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aralez (ARLZ) initiated with a Buy at Guggenheim... Atlassian (TEAM) initiated with a Neutral at Baird... CareDx (CDNA) initiated with a Buy at Janney Capital... Denison Mines (DNN) initiated with a Buy at Roth Capital... Deutsche Boerse (DBOEY) initiated with a Neutral at Exane BNP Paribas... Instructure (INST) initiated with an Outperform at Oppenheimer... Kirkland's (KIRK) initiated with a Buy at B. Riley... Mesa Labs (MLAB) initiated with a Buy at Janney Capital... Natural Grocers (NGVC) initiated with a Hold at Deutsche Bank... Nordex (NRDXF) initiated with an Overweight at Barclays... Old Line Bancshares (OLBK) initiated with a Market Perform at Keefe Bruyette... Shire (SHPG) initiated with a Neutral at Guggenheim... T2 Biosystems (TTOO) initiated with a Buy at Cantor... iRobot (IRBT) initiated with a Buy at Chardan.
09:19 EDTSHPGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Akamai (AKAM), up 16.5%... Prospect Capital (PSEC), up 10.7%... Panera Bread (PNRA), up 2%. ALSO HIGHER: Deutsche Bank (DB), up 6.1% after the Financial Times reported that the company is considering a multibillion bond buyback... Fitbit (FIT), up 3.7% after Marc Benioff reported a 5% stake in the company... FireEye (FEYE), up 3.9% after being upgraded to Buy from Neutral at BTIG... Shire (SHPG), up 1.7% after being upgraded to Outperform from Sector Perform at RBC Capital. DOWN AFTER EARNINGS: Time Warner (TWX), down 7.6%... Disney (DIS), down 5.1%... SolarCity (SCTY), down 27.8%. ALSO LOWER: CTI BioPharma (CTIC), down 38% after the FDA placed pacritinib IND on full clinical hold... Mast Therapeutics (MSTX), down 40.1% after 29.1M share Spot Unit offering priced at $0.275.
08:25 EDTSHPGShire upgraded on valuation at RBC Capital
As noted earlier, RBC Capital upgraded Shire to Outperform from Sector Perform. The firm believes that the recent decline in the stock more than accounts for any competitive risks facing the company's Baxalta drug. Target $240.
07:19 EDTSHPGShire says David Kappler to step down as deputy chairman
Subscribe for More Information
06:28 EDTSHPGShire upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information
February 9, 2016
16:14 EDTSHPGShire initiated with a Neutral at Guggenheim
09:56 EDTSHPGIntercept higher following report of vague takeover chatter
Shares of Intercept Pharmaceuticals (ICPT) are moving after United Kingdom blog Proactive Investors discussed "reheated rumours" of a takeover. "Vague talk" has Intercept teaming up with CenterView Partners to advise on a sale, the blog states. It mentions AstraZeneca (AZN) as a possible suitor now that Shire (SHPG) has reached an agreement to acquire Baxalta (BXLT). Shares of Intercept, which is developing treatments for chronic liver diseases, are up 4% to $97.39 in early trading.
February 4, 2016
16:00 EDTSHPGShire's NDA for lifitegrast for dry eye resubmssion acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the resubmission of the New Drug Application for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter received from the FDA on October 16, 2015 that requested an additional clinical study and more information related to product quality. The FDA determined that the submission is a complete response and has assigned a 6-month review period for the NDA and a Prescription Drug User Fee Act goal date of July 22.
February 3, 2016
08:07 EDTSHPGMedgenics names Brian Piper to succeed John Leaman as CFO
Subscribe for More Information
February 2, 2016
09:46 EDTSHPGIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
January 28, 2016
10:05 EDTSHPGHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use